See the DrugPatentWatch profile for Reopro
What is Reopro (abciximab) and what is it used for?
ReoPro is the brand name for abciximab, a medication used to prevent blood clots during certain heart procedures. It blocks platelet aggregation by targeting the GPIIb/IIIa receptor on platelets, helping reduce the risk of thrombotic events in the setting of angioplasty and related interventions [1].
When do doctors typically use it (e.g., during angioplasty)?
ReoPro is used in specific acute coronary and interventional cardiology situations, particularly around percutaneous coronary intervention (PCI) to lower the chance of clot-related complications [1].
How is ReoPro given?
ReoPro is administered by health professionals in a hospital setting as part of the treatment course for the procedure being performed [1].
What are the main risks and side effects people ask about?
Because ReoPro affects platelet function, bleeding is the key risk clinicians monitor for during use [1]. Other adverse effects can occur, and the full risk profile depends on the patient’s overall condition and concurrent medications used during PCI [1].
What other drugs are used alongside ReoPro?
In PCI settings, patients often receive antiplatelet and anticoagulant therapies in combination with agents like abciximab, which is one reason bleeding risk is an important consideration [1].
Is ReoPro still available, and are there alternatives?
ReoPro (abciximab) is one of several GPIIb/IIIa inhibitors used historically in interventional cardiology. Alternatives exist within the same drug class, and which one is used depends on clinical guidelines, availability, and patient factors [1].
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020062